Direct Oral Anticoagulants in Valvular Diseases and Prosthetic Valves: Why Not?

Area of Science:

• Cardiology
• Pharmacology
• Thrombosis

Background:

• Valvular heart disease (VHD) and atrial fibrillation (AF) frequently coexist, creating a prothrombotic state requiring anticoagulation.
• Vitamin K antagonists (VKAs) have been the standard, but direct oral anticoagulants (DOACs) represent a therapeutic advancement.

Purpose of the Study:

• To evaluate the role and comparative outcomes of DOACs versus VKAs in patients with AF and VHD.
• To identify specific VHD subgroups where DOACs may be viable or where VKAs remain necessary.

Main Methods:

• Review of clinical trial data comparing DOACs and VKAs in AF patients with various VHD types.
• Analysis of safety and efficacy outcomes, including thromboembolic and bleeding events.
• Consideration of guidelines and expert recommendations, such as the EHRA classification.

Main Results:

• DOACs demonstrate comparable efficacy and improved safety versus VKAs in general AF and VHD populations.
• Robust data supporting DOACs is lacking for severe mitral stenosis, mechanical valves, and rheumatic heart disease, where VKAs are preferred.
• DOACs may be suitable for patients with bioprosthetic valves or post-TAVI, pending individualized risk assessment.

Conclusions:

• DOACs offer a convenient and effective alternative to VKAs for many patients with AF and VHD.
• VKAs remain the anticoagulant of choice for specific high-risk VHD populations due to insufficient evidence for DOACs.
• Personalized risk-benefit assessment and patient-specific factors are crucial for optimizing anticoagulation therapy in this complex patient group.